Adrian Kilcoyne
Chief Medical Officer Cellectis
Seminars
Thursday 17th September 2026
Setting the Benchmark for Efficacy & Safety in CAR-T Therapy
12:25 pm
- Learnings on dual CAR-T design, why targeting CD20xCD22 simultaneously
- Rationale for NHL indication
- Present the eti-cel preliminary data
Wednesday 16th September 2026
Industry Leader’s Fireside Chat: Evaluating the CAR & TCR Therapeutic & Commercial Landscape to Propel Advanced Cell Therapy Innovation, Expand Treatment Options & Ensure Positive Commercial Outcomes
8:20 am
- Highlighting evolving modality innovations and industry shifts to demonstrate how rapid scientific and technological progress is enhancing treatment accessibility and reshaping the cell therapy landscape
- Aligning clinical development, scalability and patient access strategies to accelerate commercialization pathways across advanced cell therapy modalities
- Discussing post-approval reimbursement policies and strategies to ensure long-term commercial success
- Predicting cell therapy evolution through 2026 and beyond to provide strategic and commercial foresight
